ZIOPHARM ONCOLOGY INC Form 8-K September 26, 2007

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): September 25, 2007

### ZIOPHARM Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-32353 84-1475642

(State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.)

## 1180 Avenue of the Americas, 19<sup>th</sup> Floor New York, NY 10036

(Address of principal executive offices) (Zip Code)

#### (646) 214-0700

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 8.01. Other Events.

On September 25, 2007, ZIOPHARM Oncology, Inc. issued the press releases attached hereto as Exhibit 99.1 and Exhibit 99.2, which are incorporated herein by reference.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 99.2 Press Release dated September 25, 2007. Press Release dated September 25, 2007.

2

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 $ZIOPHARM\ Oncology,\ Inc.:$ 

(Registrant)

Date: September 26, 2007 By: /s/ Richard E. Bagley

Richard E. Bagley, President, Chief Operating Officer and Chief Financial Officer

3

# Exhibit Index

<u>Ex</u>	<u>hibit No.</u>	<u>Description</u>
	99.1	Press Release dated September 25, 2007.
	99.2	Press Release dated September 25, 2007.
4		